Chompoonut Auphimai

846 total citations
26 papers, 438 citations indexed

About

Chompoonut Auphimai is a scholar working on Infectious Diseases, Epidemiology and Animal Science and Zoology. According to data from OpenAlex, Chompoonut Auphimai has authored 26 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Infectious Diseases, 9 papers in Epidemiology and 8 papers in Animal Science and Zoology. Recurrent topics in Chompoonut Auphimai's work include SARS-CoV-2 and COVID-19 Research (15 papers), COVID-19 Clinical Research Studies (10 papers) and Animal Virus Infections Studies (8 papers). Chompoonut Auphimai is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (15 papers), COVID-19 Clinical Research Studies (10 papers) and Animal Virus Infections Studies (8 papers). Chompoonut Auphimai collaborates with scholars based in Thailand, United Kingdom and United States. Chompoonut Auphimai's co-authors include Yong Poovorawan, Preeyaporn Vichaiwattana, Nasamon Wanlapakorn, Nungruthai Suntronwong, Thanunrat Thongmee, Donchida Srimuan, Sirapa Klinfueng, Ritthideach Yorsaeng, Sitthichai Kanokudom and Suvichada Assawakosri and has published in prestigious journals such as PLoS ONE, Scientific Reports and The Journal of Infectious Diseases.

In The Last Decade

Chompoonut Auphimai

26 papers receiving 434 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chompoonut Auphimai Thailand	14	312	131	102	83	64	26	438
Teresa Aydillo United States	12	284 0.9×	386 2.9×	31 0.3×	64 0.8×	39 0.6×	26	584
Pornjarim Nilyanimit Thailand	12	221 0.7×	117 0.9×	63 0.6×	15 0.2×	47 0.7×	45	400
Donchida Srimuan Thailand	11	296 0.9×	71 0.5×	108 1.1×	7 0.1×	57 0.9×	27	362
Abdulkarim Alhetheel Saudi Arabia	12	164 0.5×	79 0.6×	18 0.2×	56 0.7×	12 0.2×	35	315
Nadine Lübke Germany	12	305 1.0×	113 0.9×	9 0.1×	54 0.7×	44 0.7×	46	432
Hamilton Bennett United States	6	283 0.9×	54 0.4×	61 0.6×	9 0.1×	50 0.8×	6	391
Carolyn M. Boudreau United States	7	184 0.6×	154 1.2×	49 0.5×	10 0.1×	21 0.3×	10	457
Jose Capellan Canada	4	170 0.5×	474 3.6×	71 0.7×	22 0.3×	15 0.2×	5	540
Han-hua Fang China	7	148 0.5×	403 3.1×	40 0.4×	32 0.4×	7 0.1×	18	448
Audrey L. Butler United States	6	165 0.5×	60 0.5×	52 0.5×	9 0.1×	19 0.3×	7	343

Countries citing papers authored by Chompoonut Auphimai

Since Specialization

Citations

This map shows the geographic impact of Chompoonut Auphimai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chompoonut Auphimai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chompoonut Auphimai more than expected).

Fields of papers citing papers by Chompoonut Auphimai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chompoonut Auphimai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chompoonut Auphimai. The network helps show where Chompoonut Auphimai may publish in the future.

Co-authorship network of co-authors of Chompoonut Auphimai

This figure shows the co-authorship network connecting the top 25 collaborators of Chompoonut Auphimai. A scholar is included among the top collaborators of Chompoonut Auphimai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chompoonut Auphimai. Chompoonut Auphimai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suntronwong, Nungruthai, Sitthichai Kanokudom, Chompoonut Auphimai, et al.. (2024). Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection. Vaccines. 12(2). 180–180. 3 indexed citations

Wanlapakorn, Nasamon, Ilada Thongpan, Preeyaporn Vichaiwattana, et al.. (2023). Epidemiology and clinical characteristics of severe acute respiratory infections among hospitalized children under 5 years of age in a tertiary care center in Bangkok, Thailand, 2019–2020. Heliyon. 9(11). e22300–e22300. 7 indexed citations

Assawakosri, Suvichada, Sitthichai Kanokudom, Nungruthai Suntronwong, et al.. (2023). Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination. Heliyon. 10(1). e23892–e23892. 5 indexed citations

Yorsaeng, Ritthideach, Nungruthai Suntronwong, Sitthichai Kanokudom, et al.. (2023). SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis. Vaccines. 11(7). 1184–1184. 8 indexed citations

Wanlapakorn, Nasamon, Nungruthai Suntronwong, Ritthideach Yorsaeng, et al.. (2022). Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study. Human Vaccines & Immunotherapeutics. 18(1). 2029111–2029111. 47 indexed citations

Assawakosri, Suvichada, Sitthichai Kanokudom, Nungruthai Suntronwong, et al.. (2022). Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination. The Journal of Infectious Diseases. 226(8). 1372–1381. 41 indexed citations

Suntronwong, Nungruthai, Ritthideach Yorsaeng, Jiratchaya Puenpa, et al.. (2022). COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron. Vaccines. 10(3). 391–391. 13 indexed citations

Assawakosri, Suvichada, Sitthichai Kanokudom, Jira Chansaenroj, et al.. (2022). Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination. International Journal of Infectious Diseases. 122. 793–801. 13 indexed citations

Kanokudom, Sitthichai, Suvichada Assawakosri, Nungruthai Suntronwong, et al.. (2022). Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine. Vaccines. 10(1). 86–86. 48 indexed citations

10.

Suntronwong, Nungruthai, Suvichada Assawakosri, Sitthichai Kanokudom, et al.. (2022). Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination. Diagnostics. 12(8). 1781–1781. 13 indexed citations

11.

Chansaenroj, Jira, Nungruthai Suntronwong, Sitthichai Kanokudom, et al.. (2022). Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine. Vaccines. 10(7). 1071–1071. 11 indexed citations

12.

Wanlapakorn, Nasamon, Nungruthai Suntronwong, Ritthideach Yorsaeng, et al.. (2022). Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data. Vaccine. 40(23). 3203–3209. 13 indexed citations

13.

Kanokudom, Sitthichai, Suvichada Assawakosri, Nungruthai Suntronwong, et al.. (2022). Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine. Vaccine. 40(39). 5657–5663. 7 indexed citations

14.

Puenpa, Jiratchaya, Kamol Suwannakarn, Jira Chansaenroj, et al.. (2021). Genetic diversity and evolution of enterovirus A71 subgenogroup C1 from children with hand, foot, and mouth disease in Thailand. Archives of Virology. 166(8). 2209–2216. 5 indexed citations

15.

Puenpa, Jiratchaya, Jira Chansaenroj, Chompoonut Auphimai, et al.. (2020). Neutralizing antibody against Enterovirus-A71 in Thai children: A longitudinal study from birth to age 4 years. Vaccine. 38(48). 7638–7644. 2 indexed citations

16.

Wanlapakorn, Nasamon, Rujipat Wasitthankasem, Preeyaporn Vichaiwattana, et al.. (2019). Antibodies against measles and rubella virus among different age groups in Thailand: A population-based serological survey. PLoS ONE. 14(11). e0225606–e0225606. 15 indexed citations

17.

Wasitthankasem, Rujipat, Preeyaporn Vichaiwattana, Nawarat Posuwan, et al.. (2018). Birth-cohort HCV screening target in Thailand to expand and optimize the national HCV screening for public health policy. PLoS ONE. 13(8). e0202991–e0202991. 11 indexed citations

18.

Wasitthankasem, Rujipat, Preeyaporn Vichaiwattana, Nawarat Posuwan, et al.. (2018). Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study. PLoS ONE. 13(4). e0196301–e0196301. 13 indexed citations

19.

Chansaenroj, Jira, Chompoonut Auphimai, Jiratchaya Puenpa, et al.. (2017). High prevalence of coxsackievirus A2 in children with herpangina in Thailand in 2015. VirusDisease. 28(1). 111–114. 17 indexed citations

20.

Wasitthankasem, Rujipat, Preeyaporn Vichaiwattana, Chompoonut Auphimai, et al.. (2017). HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs. PeerJ. 5. e4008–e4008. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact